Tapahtumakalenteri
CancerBio Summer School&Cancer IO Sebinar: Douglas Hanahan
Hallmarks of Caner - New Dimensions
Douglas Hanahan, born in Seattle, Washington, USA, received
a bachelor’s degree in Physics from MIT (1976), and a Ph.D. in Biophysics from
Harvard (1983). He worked at Cold Spring Harbor Laboratory in New York
(1978-88) initially as a graduate student and then as a group leader. From
1988-2010 he was on the faculty of the Department of Biochemistry &
Biophysics at UCSF in San Francisco. Hanahan joined the Lausanne
Branch of the Ludwig Institute for Cancer Research as a Distinguished Scholar
in January 2020. In addition, Hanahan is currently Professor and
Director of the Swiss Institute for Experimental Cancer Research within
the School of Life Sciences at EPFL, the Swiss Federal Institute
of Technology Lausanne and Co-director of the new multi-institutional
Swiss Cancer Center Leman. He has been elected to the American Academy of
Arts & Sciences (2007), the US Institute of Medicine (2008), the US
National Academy of Science (2009), and EMBO (2010). Hanahan has also
received an honorary degree from the University of Dundee in the UK (2011) and the
Lifetime Achievement Award from the AACR (2014).
The Hanahan laboratory’s research program is
structured around the use of genetically engineered mouse models (GEMMs) of
multistep de novo tumorigenesis to investigate the hallmarks of
cancer—the many distinct capabilities acquired by tumors and their constituent
cells that are essential to the establishment and progression of
cancers. The strategic plan is to elucidate the functional and phenotypic
manifestations, molecular and cellular mechanisms, and regulation of hallmark
capabilities—and to translate that knowledge into clinical applications,
diagnostics and therapies. Currently Hanahan group investigates
several organ-specific cancers, including ductal and neuroendocrine pancreatic
cancers, cervical cancer, melanoma, metastatic breast cancer and
glioblastoma. The group also have a robust program exploring the multiple
mechanisms of immune evasion employed by tumors and strategies to disable such
defenses to boost immunotherapy and broaden its applicability.
Selected publications
D. Hanahan. Hallmarks
of Cancer: New Dimensions. Cancer Discovery. 2022-01-01. DOI :
10.1158/2159-8290.CD-21-1059.
S. Saghafinia; K. Homicsko; A.
Di Domenico; S.
Wullschleger; A. Perren, et
al., D. Hanahan. Cancer Cells Retrace a Stepwise
Differentiation Program during Malignant Progression. Cancer
Discovery. 2021-10-01. DOI : 10.1158/2159-8290.CD-20-1637.
Q. Zeng; I. P. Michael; P. Zhang; S. Saghafinia; G. Knott, et al.,
D. Hanahan. Synaptic proximity enables NMDAR signalling to
promote brain metastasis. Nature. 2019-09-26. DOI :
10.1038/s41586-019-1576-6.
J. Huelsken; D. Hanahan. A
Subset of Cancer-Associated Fibroblasts Determines Therapy Resistance. Cell. 2018. DOI
: 10.1016/j.cell.2018.01.028.
S. Saghafinia; M. Mina; N. Riggi; D. Hanahan; G. Ciriello. Pan-Cancer
Landscape of Aberrant DNA Methylation across Human Tumors. Cell
Reports. 2018-10-23. DOI : 10.1016/j.celrep.2018.09.082.
K. Shchors; A. Massaras; D. Hanahan. Dual
Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed
Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit. Cancer
Cell. 2015. DOI : 10.1016/j.ccell.2015.08.012.
A. Sadanandam; C. A. Lyssiotis; K. Homicsko; E. A. Collisson; W. J. Gibb, et
al., D. Hanahan. A colorectal cancer classification system that
associates cellular phenotype and responses to therapy. Nature
Medicine. 2013. DOI : 10.1038/nm.3175.
L. Li; D. Hanahan. Hijacking
the Neuronal NMDAR Signaling Circuit to Promote Tumor Growth and Invasion. Cell. 2013. DOI
: 10.1016/j.cell.2013.02.051.
D. Hanahan; R. A. Weinberg. Hallmarks
of Cancer: The Next Generation. Cell. 2011. DOI
: 10.1016/j.cell.2011.02.013.
Find out more information on Professor Hanahan's research
and recent publications:
https://www.epfl.ch/labs/hanahan-lab/
Aloitusaika: 25.05.2022 13:00
Lopetusaika: 25.05.2022 14:00
Kesto: 1 hour
Docentship lecture: Takashi Namba
"Adult
neurogenesis in the human hippocampus: Death of a dogma or not?”
Length
is 30min, after which there is discussion, and then the audience will evaluate
the lecture.
Aloitusaika: 25.05.2022 14:00
Lopetusaika: 25.05.2022 15:00
Kesto:
Lisätiedot:
Online-kokouslinkki:
Dissertation: Pauliina Reijonen
Pauliina Reijonen, University of Helsinki, Faculty of Medicine, Doctoral Program in Clinical ResearchRisk factors of successful liver metastasectomy in colorectal cancer
Opponent: doent Marja Hyöty, University of Tampere
Aloitusaika: 27.05.2022 12:00
Lopetusaika: 27.05.2022 14:00
Kesto: 1 hour
Dissertation: Liisa Harjama
Liisa Harjama, University of Helsinki, Faculty of Medicine, Doctoral Program in Clinical ResearchHereditary palmoplantar keratoderma in Finland
Opponent: professor Edel O'Toole, Queen Mary University of London
Aloitusaika: 27.05.2022 12:00
Lopetusaika: 27.05.2022 14:00
Kesto: 2 hours
Dissertation: Elisa Hackenberg
Elisa Hackenberg, University of Helsinki, Faculty of Medicine, Doctoral Program in Clinical Research Trauma-informed care for injuries after intimate partner violence
Opponent: associate professor Joonas Sirola, University of Kuopio
Aloitusaika: 27.05.2022 12:00
Lopetusaika: 27.05.2022 14:00
Kesto: 2 hours